Equibles does not estimate personal net worth.
Get an email with a short summary when Bionano Genomics, Inc. publishes a filing, an earnings call transcript or a press release.
Get BNGO alertsAlbert A. Luderer, Ph.D. is recorded as CEO and CFO at Bionano Genomics, Inc. (BNGO) since May 5, 2026. Bionano Genomics, Inc. reported in an 8-K filed May 6, 2026 that Albert A. Luderer, Ph.D. was appointed Interim Chief Executive Officer, effective May 5, 2026. Albert A. Luderer, Ph.D. has spoken on 2 earnings calls across 1 company, most recently for Bionano Genomics, Inc. on August 10, 2026. Bionano Genomics, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Bionano Genomics, Inc. includes R. Erik Holmlin (CEO and Board Member), Albert Luderer (Chairman), Gülsen Kama (CFO) and 7 others.
“As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company's Chairman of the Board, as the Company's Interim Chief Executive Officer.”
“Reconciliations of these measures to GAAP can be found on our press release and slide deck an audio recording and webcast replay of today's conference call will also be available online on the investor relations page of the company website with that i will turn the call over to al well thank you web and good afternoon…”
“I'm pleased to be here with you all today. Before I share an update on our first quarter, I want to address the recent leadership transition. As announced last week, I'm stepping in as interim CEO and will maintain my role as chairman.”
2026-05-05–present
2026-05-05–present
Medical Instruments & Supplies · Healthcare
CEO, CFO
2026-05-05–present
